French Authorities Expand Meningitis Vaccine Coverage, Launch Catch-Up Program
In response to a recent surge in meningitis cases, and mirroring concerns over outbreaks in the United Kingdom, French health authorities have announced expanded coverage for vaccinations against several strains of the disease. Effective immediately, the vaccines Bexsero and Menveo are now reimbursed by the national health insurance system (Sécurité Sociale) for a wider range of at-risk individuals, and a temporary catch-up program has been initiated for children born between 2020 and 2022. This move aims to bolster protection against invasive meningococcal infections, a potentially life-threatening inflammation of the membranes surrounding the brain and spinal cord.
The decision, formalized in an arrêté published in the Journal officiel on March 12, 2026, extends financial assistance for these vaccines to individuals with specific immune deficiencies, those without a spleen (asplenia), and patients who have undergone stem cell transplants. Crucially, the reimbursement likewise covers a temporary catch-up vaccination campaign targeting children born in 2020, 2021, and 2022, who are considered to be at heightened risk. This proactive measure underscores the government’s commitment to public health and preventative medicine in the face of evolving epidemiological challenges.
Expanded Reimbursement Details and Eligible Groups
Bexsero, designed to protect against group B meningococcal infections, and Menveo, which targets groups A, C, W, and Y, join Nimenrix in being covered by the Assurance Maladie. The reimbursement isn’t universal; it’s specifically tailored to individuals facing increased vulnerability. According to the official decree, eligible individuals include those with specific immune system deficits affecting complement or properdine pathways, adults who have had their spleens removed, and patients who have received stem cell transplants. Individuals who meet the vaccination recommendations set forth by the Haute Autorité de Santé (HAS) – the French national public health authority – are also eligible for coverage.
The temporary catch-up program for children born in 2020, 2021, and 2022 is a direct response to concerns about increased susceptibility within this age group. Health officials emphasize that early vaccination is crucial in preventing the spread of these potentially devastating infections. The French Ministry of Health has not yet released specific details regarding the logistical implementation of this catch-up program, but further information is expected in the coming weeks.
Mandatory Vaccination Policies and Recent Uptake
The expanded reimbursement and catch-up program build upon existing mandatory vaccination policies implemented in France. Since January 1, 2025, vaccination against meningococcal ACWY has been compulsory for all infants born on or after January 1, 2023, even those previously vaccinated against meningococcal C. Similarly, vaccination against meningococcal B became mandatory for all babies born on or after the same date. These policies reflect a broader strategy to proactively combat the spread of meningococcal disease and protect the most vulnerable populations.
Evidence from other countries supports the effectiveness of widespread vaccination programs. According to data cited by the French Ministry of Health, vaccination programs in England have led to an approximately 80% reduction in new cases among young children following the implementation of a complete vaccination schedule (three doses against invasive group B meningococcal infections) during the first three years of the program. Similarly, the Netherlands experienced an 82% decrease in new cases among young children after replacing vaccination against group C meningococcus with vaccination against groups ACWY. These findings underscore the significant public health benefits of comprehensive vaccination strategies.
Rising Meningitis Cases Prompt Action
The recent policy changes are directly linked to a concerning increase in invasive meningococcal infections. According to a report from Santé Publique France published on April 24, 2025, 616 cases of meningitis were reported in 2024, representing a 10% increase compared to 2023. This is the highest annual number of cases recorded since 2010, raising alarm among public health officials. Meningitis B is most prevalent among infants and young children aged one to four years, with a secondary peak in young adults aged 15-24. Meningitis W and Y are more commonly observed in infants and individuals over the age of 80.
Understanding the different types of meningococcal disease is crucial for effective prevention. Meningitis can be caused by several different bacteria, viruses, or fungi. Bacterial meningitis, in particular, is a serious infection that can lead to severe complications, including brain damage, hearing loss, and even death. Early diagnosis and treatment with antibiotics are essential for improving outcomes.
Understanding Meningococcal Disease and Prevention
Meningococcal disease is transmitted through close, prolonged contact with an infected person or carrier via respiratory droplets – through coughing, sneezing, or saliva. This makes vaccination the most effective preventative measure. The vaccines Bexsero and Menveo stimulate the immune system to produce antibodies that protect against specific strains of the bacteria, reducing the risk of infection and severe illness.
According to the Haute Autorité de Santé (HAS), Bexsero is available for use starting at 2 months of age, while Menveo is recommended for individuals aged 2 years and older. Detailed product information, including contraindications and potential side effects, is available from the HAS.
While vaccination is the primary defense, practicing excellent hygiene – such as frequent handwashing and covering coughs and sneezes – can also help reduce the risk of transmission. Individuals experiencing symptoms of meningitis, such as high fever, severe headache, stiff neck, and sensitivity to light, should seek immediate medical attention.
The French government’s proactive approach to expanding vaccine coverage and implementing catch-up programs demonstrates a strong commitment to protecting public health. As the situation continues to evolve, ongoing monitoring and adaptation of vaccination strategies will be crucial in mitigating the impact of meningococcal disease. Further updates regarding the implementation of the catch-up program for children born in 2020, 2021, and 2022 are expected from the Ministry of Health in the coming weeks.
Key Takeaways:
- Bexsero and Menveo vaccines are now reimbursed in France for at-risk individuals and as part of a catch-up program for children born 2020-2022.
- Meningitis cases in France rose 10% in 2024, reaching the highest level since 2010.
- Mandatory vaccination policies for meningococcal ACWY and B are in place for infants born since January 1, 2023.
- Early vaccination and prompt medical attention for symptoms are crucial for preventing severe complications.
The French health authorities will continue to monitor the situation closely and provide updates as needed. Readers are encouraged to consult with their healthcare providers for personalized advice regarding meningitis vaccination. Share this information with your network to help raise awareness about this important public health issue.